Review article · 2016 · Open access
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Breast Care, 11(6), 385–390 · Published 1 January 2016 · DOI 10.1159/000453569
In brief
“PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer” is a 2016 review article by Andreas Daniel Hartkopf and 6 co-authors, published in Breast Care. OpenAlex counts 30,989 citations as of 15 November 2026, which puts it in the top 1% of works published in 2016 by citations. It is open access: the full text is free to read at Breast Care.
- Citations
- 30,989
- Most cited in
- 2022 (4,114)
- Field-weighted impact
- 389.65
- References
- 70
- Authors
- 7
Abstract
Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especially in the triple-negative subtypes of breast cancer (TNBC). Although immune checkpoint blockade is generally well tolerated, specific immune-related adverse events (irAEs) may occur. This review summarizes the clinical efficacy, perspectives, and future challenges of using PD-1/PD-L1-directed antibodies in the treatment of breast cancer.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016). PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer. Breast Care, 11(6), 385–390. https://doi.org/10.1159/000453569
MLA 9
Hartkopf, Andreas Daniel, et al. “PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer.” Breast Care, vol. 11, no. 6, 2016, pp. 385–390. https://doi.org/10.1159/000453569.
Chicago
Hartkopf, Andreas Daniel, Florin‐Andrei Taran, Markus Wallwiener, Christina Barbara Walter, Bernhard Krämer, Eva‐Maria Grischke, and Sara Yvonne Brucker. 2016. “PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer.” Breast Care 11 (6): 385–390. https://doi.org/10.1159/000453569.
Harvard
Hartkopf, A. D. et al. (2016) ‘PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer’, Breast Care, 11(6), pp. 385–390. doi:10.1159/000453569.
IEEE
A. D. Hartkopf et al., “PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer,” Breast Care, vol. 11, no. 6, pp. 385–390, 2016, doi: 10.1159/000453569.
BibTeX
@article{hartkopf2016immune,
title = {{PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer}},
author = {Hartkopf, Andreas Daniel and Taran, Florin‐Andrei and Wallwiener, Markus and Walter, Christina Barbara and Krämer, Bernhard and Grischke, Eva‐Maria and Brucker, Sara Yvonne},
journal = {Breast Care},
year = {2016},
volume = {11},
number = {6},
pages = {385--390},
doi = {10.1159/000453569},
url = {https://doi.org/10.1159/000453569}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2017 | 2,821 | |
| 2018 | 2,971 | |
| 2019 | 2,990 | |
| 2020 | 2,614 | |
| 2021 | 3,096 | |
| 2022 | 4,114 | |
| 2023 | 3,275 | |
| 2024 | 2,561 | |
| 2025 | 891 | |
| 2026 | 10 |
Its field-weighted citation impact is 389.65: it has been cited 389.65 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- PD-1
- PD-L1
- immune checkpoint blockade
- breast cancer
- triple-negative breast cancer
- immune-related adverse events
- anti-PD-1
- antitumor immunity
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016). PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer. Breast Care, 11(6), 385–390. https://doi.org/10.1159/000453569
How many times has this paper been cited?
30,989 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access: read the free full text at Breast Care.
Who wrote this paper?
Andreas Daniel Hartkopf, Florin‐Andrei Taran, Markus Wallwiener, Christina Barbara Walter, Bernhard Krämer, Eva‐Maria Grischke, Sara Yvonne Brucker.
What is the DOI of this paper?
10.1159/000453569. The permanent link is https://doi.org/10.1159/000453569.
Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.